# ALPACCA: HCP commentary report

> 13 verified statements (11 from clinicians verified by NPI or staff page) from 5 commentary sources · 4 findings · updated Nov 1, 2026

## Report

- Trial: A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of Osimertinib or Afatinib as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations (ALPACCA)
- NCT ID: NCT07185997
- Registry: https://clinicaltrials.gov/study/NCT07185997
- Sponsor: ArriVent BioPharma, Inc.
- Phase: Phase 3
- Status: Recruiting
- Drugs tested: firmonertinib
- Indication: first-line locally advanced or metastatic EGFR PACC NSCLC
- Version: v1.0.0, edition 1
- Accepted: 2026-11-01
- Last checked: 2026-11-01
- Release hash: 1bb154d22fb807d48536d1616c2d4a1d42b4589d71929e24b1a8aaf70a46e271

## Counts

- HCP commentary sources screened: 12
- Sources cited by verified statements: 5
- Verified statements: 13
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 11
- Findings: 4
- Named people in screened sources (unnamed speakers and accounts not counted): 3
- Voices cited: 3
- Cited voices identity-verified: 3
- Organisational or shared accounts (not counted as people): 1

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

ALPACCA compares first-line firmonertinib with osimertinib or afatinib in locally advanced or metastatic EGFR PACC-mutant NSCLC; commentary includes a conditional global-approval question, not an ALPACCA failure report. The report cites two medical oncologists, one described in the source as involved in ALPACCA. Further discussion asks why dedicated randomized PACC evidence is welcomed and how earlier activity signals should be interpreted. What can Medical Affairs say about development and treatment options without turning those signals or cross-setting approval questions into ALPACCA conclusions?

## Open Medical Affairs question

What can Medical Affairs say about ALPACCA's development and treatment-option rationale without turning earlier activity signals or a cross-setting approval question into an ALPACCA conclusion?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Ou raises a conditional global-approval question—not an ALPACCA failure report
- F2. Earlier efficacy signals and comparator attributes are background—not ALPACCA results
- F3. The dedicated randomized program is welcomed as progress toward mutation-specific care
- F4. Le presents resistance research and collaboration as the next development step

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 1 | 1 | 1 | 1 | none recorded | 2 |
| F2 | 5 | 3 | 3 | 3 | none recorded | 3 |
| F3 | 6 | 4 | 4 | 4 | none recorded | 3 |
| F4 | 2 | 2 | 2 | 2 | none recorded | 2 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 post or article | yes |
| F2 | 2 | 0 | 2 | 0 | 1 | 5 | 3 | 3 posts and articles | yes |
| F3 | 4 | 0 | 1 | 0 | 1 | 7 | 0 | 4 posts and articles | yes |
| F4 | 2 | 0 | 0 | 0 | 0 | 4 | 0 | 2 posts and articles | yes |

### Trial dimensions

- Primary endpoint: Progression Free Survival (PFS) determined by blinded independent central review (BICR): no finding draws on it directly
- Primary endpoint: Confirmed overall response rate (ORR) as determined by BICR: no finding draws on it directly
- Secondary endpoints: no finding draws on it directly
- Population and setting: F1 (1 shared claims), F2 (2 shared claims), F3 (4 shared claims)
- The comparison: F2 (2 shared claims)
- Safety and tolerability: no finding draws on it directly
- Design and conduct: F3 (4 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

### F1. Ou raises a conditional global-approval question—not an ALPACCA failure report

An X post asks about the possibility of global approval across disease settings.

Source: X thread, 2026-10-07.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 4 | Titles free |
| Detailed analysis | 5 sections | Paid |
| Verified statements with short source quotes and links | 13 | Paid |
| Trial aspects mapped | 11 | Free |
| Sources with links | 5 | Counts free |
| Speaker attribution for cited voices | 3 | Paid |

## Trial aspects

7 discussed · 4 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Progression Free Survival (PFS) determined by blinded independent central review (BICR) | no commentary found | 0 | 0 |
| Primary endpoint: Confirmed overall response rate (ORR) as determined by BICR | no commentary found | 0 | 0 |
| Secondary endpoints | no commentary found | 0 | 0 |
| Population and setting | discussed | 6 | 5 |
| The comparison | discussed | 2 | 1 |
| Safety and tolerability | no commentary found | 0 | 0 |
| Design and conduct | discussed | 4 | 4 |
| Earlier prospective activity—not ALPACCA results | discussed | 3 | 3 |
| Stage-specific development and the global-approval question | discussed | 1 | 1 |
| Prospective response-and-resistance research | discussed | 2 | 2 |
| Unmet need and chemotherapy-free positioning | discussed | 1 | 1 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 9 | 4 |
| Bluesky threads | 2 | 0 |
| LinkedIn posts | 1 | 1 |

- Screened window: 2025-12-04 to 2026-10-07
- Cited window: 2025-12-04 to 2026-10-07
- Retrieved: 2026-11-01

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of Osimertinib or Afatinib as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations (ALPACCA)
- Registry: NCT07185997 (https://clinicaltrials.gov/study/NCT07185997)
- Study IDs: FURMO-006
- Sponsor: ArriVent BioPharma, Inc.
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Recruiting
- Enrollment: 480 (estimated)
- Start: 2025-12-17 (actual)
- Primary completion: 2029-02 (estimated)
- Primary endpoint: Progression Free Survival (PFS) determined by blinded independent central review (BICR) (Until progression or death, assessed up to approximately 4 years)
- Primary endpoint: Confirmed overall response rate (ORR) as determined by BICR (Until progression or death, assessed up to approximately 3 years)
- Intervention: Firmonertinib (drug)
- Intervention: EGFR-TKI inhibitor based on investigator's choice (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 6 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits apply, so some matching discussion may be missing.
- Discussion centered on ALPACCA and its registry names may miss relevant views expressed without those names or with other wording.
- Some passages were not fully assessed for clinician views, so the report is not a complete account of the clinical decision or public discussion.
- Repeated posts and reposts do not establish independent agreement or the prevalence of a view.
- Le is described in the source as involved in ALPACCA; this is source-described involvement, not an independently confirmed trial role.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- The earlier efficacy studies are not named in the relevant posts. Their populations, assessment details and comparability cannot be reconstructed from these statements.
- No full protocol or results publication for the exact trial was available in the sources reviewed. Regulatory labels matching the intervention names as searched were not identified; that absence does not establish lack of approval.
- The sources provide no ALPACCA efficacy or safety outcome, no comparative CNS estimate and no answer to the global-approval question.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-11-01: current edition

Last checked for new commentary 2026-11-01. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (13 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (3 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/alpacca-nct07185997
- Agents: POST https://www.erudio.com/api/orders with {"report": "alpacca-nct07185997", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=alpacca-07185997

## Cite

Erudio Health. ALPACCA (NCT07185997): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 1, 2026. https://www.erudio.com/reports/alpacca-nct07185997

## Machine access

- JSON: https://www.erudio.com/reports/alpacca-nct07185997.json
- Markdown: https://www.erudio.com/reports/alpacca-nct07185997.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "alpacca-07185997"}`